Mike Exton, CEO and Board Director of Lexicon Pharmaceuticals, talks about safeguards and limits for AI, smaller pharma veresus big pharma, and brand strategies based on data over belief.

Gordon McCauley, CEO of adMare BioInnovations, unpacks the profits, principles, and policies shaping today’s life sci industry.

Casey James Lawton, General Manager at Peirre Fabre Dermo-Cosmetic, talks about diverse career experiences, learning to pivot, and building strong, science-driven foundations.

Fatih Yetikardes, Country Manager of Daiichi Sankyo, gives insights into advancing patient care with company collaborations, the unique complexities of the Canadian healthcare system, and the ethical use and transparent governance of AI.

Bob McLay, General Manager of Sobi Canada, gives insights into stewarding rare drug therapies, KOL advocacy and the future of preventative medicine.

Marc Shenouda, CEO and Co-Founder of Neuropeutics Inc., gives insights into targeted therapeutics for neurodegenerative disease, winning the AbbVie Biotech Innovator’s Award, and earlier detection for ALS.

Dr. Bettina Hamelin, President of Innovative Medicines Canada, gives insights into the adoption of innovative technologies, domestic supply chain for pharmaceuticals, and excluding medicines as retaliatory measures for tariffs.

Paul Levesque, President and CEO of Theratechnologies Inc., gives insights into innovation in biopharma, the effects of tariffs on supply chain and pharma manufacturing, and cross-border business development.